Table 1. Demographics of ALLHAT participants with ECG at baselinea.
| Characteristic | Chlorthalidone (n = 12,102) | Amlodipine (n = 7,151) | P (A vs C) | Lisinopril (n = 7,123) | P (L vs C) |
|---|---|---|---|---|---|
| Age, years, mean (SD) | 66.71 (7.57) | 66.65 (7.58) | 0.5942 | 66.66 (7.60) | 0.6231 |
| Age range, years, mean (SD) | 0.638 (chi-square for all categories) | ||||
| 55-64 | 5,238 (43.28) | 3,120 (43.63) | 3,113 (43.70) | 0.569 | |
| ≥ 65 | 6,864 (56.72) | 4,031 (56.37) | 4,010 (56.30) | ||
| Race, n (%) | 0.729 (chi-square for all categories) | 0.724 | |||
| White, non-Hispanic | 6,018 (49.73) | 3,564 (49.84) | 3,540 (49.70) | ||
| Black, non-Hispanic | 3,772 (31.17) | 2,253 (31.51) | 2,262 (31.76) | ||
| White Hispanic | 1,383 (11.43) | 805 (11.26) | 785 (11.02) | ||
| Black Hispanic | 327 (2.70) | 202 (2.82) | 201 (2.82) | ||
| Other | 602 (4.97) | 327 (4.57) | 335 (4.70) | ||
| Women, n (%) | 5,578 (46.09) | 3,354 (46.90) | 0.276 | 3,272 (45.94) | 0.834 |
| Education, years, mean (SD) | 11.10 (4.02) | 11.09 (3.89) | 0.8615 | 11.09 (4.03) | 0.9069 |
| Receiving antihypertensive treatment, n (%) | 10,903 (90.09) | 6,443 (90.10) | 0.988 | 6,410 (89.99) | 0.819 |
| Blood pressure, mm Hg, mean (SD) | |||||
| Systolic | 146.21 (15.67) | 146.24 (15.59) | 0.8931 | 146.30 (15.54) | 0.7022 |
| Diastolic | 84.14 (10.03) | 84.16 (10.12) | 0.8888 | 84.22 (10.01) | 0.5903 |
| Treated at baseline | |||||
| Systolic | 145.13 (15.66) | 145.11 (15.61) | 0.9207 | 145.21 (15.50) | 0.7379 |
| Diastolic | 83.55 (9.96) | 83.53 (10.00) | 0.8933 | 83.67 (9.94) | 0.4421 |
| Untreated at baseline | |||||
| Systolic | 155.98 (12.04) | 156.52 (12.22) | 0.3401 | 156.02 (12.20) | 0.9417 |
| Diastolic | 89.49 (9.00) | 89.90 (9.35) | 0.3468 | 89.16 (9.28) | 0.4327 |
| Eligibility risk factors, n (%) | |||||
| Cigarette smoker | 2,713 (22.42) | 1,580 (22.09) | 0.603 | 1,572 (22.07) | 0.575 |
| Atherosclerotic CVD | 6,224 (51.43) | 3,625 (50.69) | 0.323 | 3,632 (50.99) | 0.556 |
| History of MI or stroke | 2,841 (23.48) | 1,641 (22.95) | 0.403 | 1,608 (22.57) | 0.153 |
| History of coronary revascularization | 1,587 (13.11) | 876 (12.25) | 0.083 | 936 (13.14) | 0.957 |
| Other atherosclerotic CVD | 2,753 (22.75) | 1,643 (22.98) | 0.716 | 1,628 (22.86) | 0.864 |
| Major ST depression or T-wave inversion | 1,285 (10.72) | 737 (10.41) | 0.496 | 756 (10.73) | 0.991 |
| Type 2 diabetes | 4,264 (35.23) | 2,542 (35.55) | 0.660 | 2,450 (34.40) | 0.239 |
| HDL-C < 35 mg/dl | 1,458 (12.05) | 842 (11.77) | 0.573 | 872 (12.24) | 0.690 |
| History of CHD at baseline, n (%) | 3,115 (25.95) | 1,718 (24.21) | 0.008 | 1,736 (24.58) | 0.036 |
| Body mass index, mean (SD) | 29.64 (6.01) | 29.89 (6.31) | 0.0065 | 29.77 (6.15) | 0.1539 |
| Current medication use, n (%) | |||||
| Aspirin | 4,374 (36.14) | 2,638 (36.89) | 0.376 | 2,609 (36.63) | 0.683 |
| Estrogen supplementation (women only) | 1,067 (19.13) | 628 (18.73) | 0.463 | 591 (18.06) | 0.296 |
| Lipid trial participants, n (%) | 3,093 (25.56) | 1,839 (25.72) | 0.807 | 1,786 (25.07) | 0.456 |
a
Included individuals must have the following: a baseline ECG, a valid Cornell voltage on baseline ECG, and no Cornell voltage suppression codes at baseline.